ZA201601656B - Inhalable pharmaceutical composition - Google Patents

Inhalable pharmaceutical composition

Info

Publication number
ZA201601656B
ZA201601656B ZA2016/01656A ZA201601656A ZA201601656B ZA 201601656 B ZA201601656 B ZA 201601656B ZA 2016/01656 A ZA2016/01656 A ZA 2016/01656A ZA 201601656 A ZA201601656 A ZA 201601656A ZA 201601656 B ZA201601656 B ZA 201601656B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
inhalable pharmaceutical
inhalable
composition
pharmaceutical
Prior art date
Application number
ZA2016/01656A
Inventor
Preeti Raut
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of ZA201601656B publication Critical patent/ZA201601656B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2016/01656A 2015-03-10 2016-03-10 Inhalable pharmaceutical composition ZA201601656B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN770MU2015 2015-03-10

Publications (1)

Publication Number Publication Date
ZA201601656B true ZA201601656B (en) 2017-06-28

Family

ID=55543006

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/01656A ZA201601656B (en) 2015-03-10 2016-03-10 Inhalable pharmaceutical composition

Country Status (2)

Country Link
WO (1) WO2016142708A2 (en)
ZA (1) ZA201601656B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109077998B (en) * 2017-06-13 2023-02-03 恩康药业科技(广州)有限公司 Salmeterol lipid complex and preparation method thereof
CN109758436A (en) * 2017-11-09 2019-05-17 北京盈科瑞创新药物研究有限公司 A kind of Neulized inhalation pirfenidone freeze-dried lipidosome preparation and preparation method thereof
CN109758437A (en) * 2017-11-09 2019-05-17 北京盈科瑞创新药物研究有限公司 A kind of Neulized inhalation Nintedanib freeze-dried lipidosome preparation and preparation method thereof
CN108175764B (en) * 2017-12-19 2020-02-21 亿腾医药(苏州)有限公司 Anhydrous beclomethasone dipropionate sterile powder and preparation method of inhalation suspension
WO2019202400A1 (en) * 2018-04-17 2019-10-24 Universite De Caen Normandie Bambuterol for the treatment of alzheimer's disease
CN110742875B (en) * 2018-07-05 2022-09-30 北京盈科瑞创新药物研究有限公司 Pirfenidone solution preparation for inhalation and preparation method and application thereof
CN112823009A (en) * 2019-08-28 2021-05-18 上海谷森医药有限公司 Fluticasone furoate liposome preparation and preparation method thereof
WO2021150471A1 (en) * 2020-01-20 2021-07-29 Huang Cai Gu Liposome formulation of vilanterol trifenatate
CN111729087A (en) * 2020-07-24 2020-10-02 成都大学 Lipid modification of a selective β2 receptor agonist and preparation method and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258499A (en) * 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2002083840A2 (en) * 2001-04-03 2002-10-24 Arizeke Pharmaceuticals, Inc. Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
AU2003230689B2 (en) * 2002-03-20 2006-06-29 Alkermes, Inc. Inhalable sustained therapeutic formulations
CA2898700C (en) 2013-03-14 2022-07-19 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug

Also Published As

Publication number Publication date
WO2016142708A3 (en) 2016-12-29
WO2016142708A2 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
IL265260B (en) Pharmaceutical composition
IL265360A (en) Pharmaceutical composition
IL262654A (en) Pharmaceutical composition
GB201409471D0 (en) Pharmaceutical composition
ZA201601656B (en) Inhalable pharmaceutical composition
GB201409488D0 (en) Pharmaceutical composition
IL265349A (en) Pharmaceutical composition
GB201409485D0 (en) Pharmaceutical composition
HUE046729T2 (en) Pharmaceutical composition containing mirabegron
GB201521462D0 (en) Pharmaceutical composition
GB201506526D0 (en) Medicinal composition
IL263040A (en) Pharmaceutical composition comprising eteplirsen
PL3313370T3 (en) Ophthalmologic pharmaceutical composition
ZA201508726B (en) Pharmaceutical composition
ZA201502073B (en) Pharmaceutical composition
IL255510A (en) Pharmaceutical compositions
PL3454838T3 (en) Pharmaceutical composition
GB201615917D0 (en) Pharmaceutical composition
GB201515310D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
GB201520862D0 (en) Pharmaceutical composition
LT3089740T (en) Pharmaceutical composition
GB201615910D0 (en) Pharmaceutical composition
SG10201504332VA (en) Pharmaceutical Composition
ZA201500995B (en) Low dose pharmaceutical composition